

Bhageria & Jajodia Pharmaceuticals Private Limited					
UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026					
(Rs. in Lakhs Except EPS)					
PARTICULARS		Quarter Ended			Year Ended
		(Unaudited)	(Unaudited)	(Audited)	(Audited)
		30-06-2026	31-03-2026	30-06-2025	31-03-2026
1	Revenue from operations (Net of GST)	54.43	33.45	126.93	225.41
2	Other income	2.04	2.11	2.10	8.48
3	Total Income (1+2)	56.47	35.56	129.04	233.88
4	Expenses				
	Cost of materials consumed	-	-	-	-
	Purchase of Stock-in-Trade	70.25	99.76	178.94	419.56
	Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	-	-	-	-
	Employee benefit expense	0.50	0.76		2.83
	Finance costs	34.20	31.88	27.85	119.37
	Depreciation and amortization expense	-	-	-	-
	Other expenses	0.67	12.97	1.10	16.57
	Total expenses	105.61	145.37	207.88	558.33
5	Profit before tax (3-4)	(49.15)	(109.81)	(78.84)	(324.45)
6	Tax expense:	-	-	-	-
	Current tax	-	-	-	-
	Deferred tax	-	-	-	-
	(Excess) / Short Provision for tax	-	-	-	-
7	Profit for the period (5-6)	(49.15)	(109.81)	(78.84)	(324.45)
8	Other comprehensive income				
	Items that will not be reclassified to profit or loss				
	i. Remeasurement of the defined benefit plans	-	-	-	-
	ii. Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-
	Total other comprehensive income for the period (net of tax)(i+ii)	-	-	-	-
9	Total Comprehensive Income for the period (7+8)	(49.15)	(109.81)	(78.84)	(324.45)
10	Paid up Capital				
	Face value of share (Rs.)	10.00	10.00	10.00	0.00
11	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-
12	Earnings per equity share (EPS) :				
	Basic EPS (Rs) (not annualised)	(9.83)	(21.96)	(15.77)	(64.89)
	Diluted EPS (Rs) (not annualised)	(9.83)	(21.96)	(15.77)	(64.89)
	Face value of share (Rs)	10.00	10.00	10.00	10.00